Pharmacokinetic, Pharmacodynamic and Interleukin Profile of Intramuscularly Administered BP-C1 in Women With Metastatic Breast Cancer: A Phase I(D) Study

Trial Profile

Pharmacokinetic, Pharmacodynamic and Interleukin Profile of Intramuscularly Administered BP-C1 in Women With Metastatic Breast Cancer: A Phase I(D) Study

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs BP-C1 (Primary)
  • Indications Breast cancer
  • Focus Pharmacokinetics
  • Sponsors Meabco
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Feb 2017 Timeframe of Primary endpoint has been changed from Day -1, Day 1, Day 8, Day 16, Day 24, Day 32 to Pre-dose, 10, 20, 30, 35, 40, 45, 60, 120 min and 6, 24, 48 hours post dose and primary end points has also added.
    • 12 Feb 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top